Testosterone Enanthate / TESTO 250 - Unit: 10 x 1 ml Amps(250 mg/ml)
Active Ingredient: Testosterone
Pack: 10 x 1 ml Amps(250 mg/ml)
Half Life: 10 days
Detection Time: 3 months
Anabolic Rating: 100
Androgenic Rating: 100
Dosage: male 300-1000 mg per week, female - not recommended.
Common brands: Testosterone Enanthate, Testosterona E, Testosterone E, Test E, Testo E, Enanthate, Pharmatest E, Testover E, Testoviron, Testoviron Depot, Testosteron Depo, Test, Test 300, Testaplex E, Enanta-Med, Depo-Test, TE, Enalan, Testoged-E, Testabol, Enanthate, Testenat, Testenat Depot, Testo-Enan, Cidoteston, EnanSam, Testofort, Enanthal, Primoteston, Testen, Enanline, Androgen, Andro, GP Test Enan, Teston E
TESTO 250® is a steroid compound that is described chemically as 17(3-Hydroxyandrost-4- en-3-one heptanoate. It is the principal hormone of the testis. The ester, Enanthate, is a stable, white or yellowish-white crystalline powder that is insoluble in water but very soluble in dehydrated alcohol, freely soluble in fatty oil and dichloromethane. Esterification of the 17 beta-hydroxy group produces compounds which have a longer duration of action.
TESTO 250® is a sterile solution of Testosterone Enanthate USP29, Ph.Eur.5.5 Micronized grade in Miglyol 840, Ethyl oleate, Benzyl benzoate, Benzyl alcohol.
Endogenous androgens are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as the beard, and pubic, chest, and axillary hair, laryngeal enlargement, vocal-cord thickening; alterations in body musculature; and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorus and decreased urinary excretion of calcium. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.
Androgens are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).
There is lack of substantial evidence that androgens are effective in fractures, surgery, convalescence, and functional uterine bleeding.
TESTO 250® is less polar than free testosterone. TESTO 250® in oil injected intramuscularly is absorbed slowly from the lipid phase; thus, it can be given at intervals of 2 to 3 times perweek.
Testosterone in plasma is 98% bound to a specific testosterone estradiol binding globulin, and about 2% is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine half-life.
About 90% of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-ketosteroids through two different pathways. The half-life of testosterone as reported in the literature varies considerably; it ranges from 10 to 100 minutes.
In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where is initiates transcription events and cellular changes related to androgen action.
INDICATIONS AND USAGE:
Males: TESTO 250® is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:
A. Primary hypogonadism (congenital or acquired) -testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy.
B. Hypogonadotropic hypogonadism (congenital or acquired) - idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will require to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.
C. TESTO 250® may be used to stimulate puberty in carefully selected males with clearly delayed puberty that is not secondary to a pathologic disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychologic support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (See WARNINGS).
Females: TESTO 250® may be used secondarily in women with advancing in operable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy.
This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgement concerning androgen therapy should be made by an oncologist with expertise in this field.
TESTO 250® has been used for the management of postpartum breast pain and engorgement. (There is no satisfactory evidence that this drug prevents or suppresses lactation.)
TESTO 250® is contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of masculinization is related to the amount of drug given and the age of the fetus and is most likely to occur in the female fetus when the drugs are given in the first trimester. If the patient becomes pregnant while taking these drugs, she should be apprised of the potential hazard of the fetus.
In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis. In this case, the drug should be discontinued.
Prolonged use of high doses of androgens has been associated with the development of peliosis hepatitis and hepatic neoplasms, including hepatocellular carcinoma (See PRECAUTIONS-Carcinogenesis). Peliosis hepatic can be a life-threatening or fatal complication.
Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma.
Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
Gynecomastia frequently develops and occasionally persists in patients being treated for hypogonadism.
Androgen therapy should be used cautiously in healthy males with delayed puberty. The effect on bone maturation should be monitored by addressing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature, the younger child and the greater risk of compromising final mature height.
Do not give TESTO 250® to elderly asthenic males who may react adversely to overstimulation by androgens.
General Precautions: TESTO 250® , through its metabolic effects, stimulates the nervous, mental, and physical activities of a patient. Therefore, it should be used with caution in the presence of cardiovascular and renal diseases, especially in the elderly male.
Prolonged administration or excessive dosage may cause inhibition of testicular function. As the result, oligospermia may develop, and there may be a decrease in ejaculatory volume. Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, clitoromegaly, and menstrual irregularities). Discontinuation of drug therapy at the time mild virilism becomes evident is necessary to prevent irreversible virilization. Such virilization usually follows administration of androgens at high doses. A decision may be made by the patient and the physician concerning the degree of virilization that will be tolerated during treatment for breast carcinoma.
Anaphylactoid reactions, although rare, may occur, and treatment should be readily available.
Hypersensitivity reaction including rash and dermatitis, have been reported.
Special Precautions: Regular exam of the prostate. Benign rarely, malignant liver tumour which may lead to intraabdominal hemorrhage. Unusual severe upper abdominal complaints. Not suitable for enhancing muscular development.
Information for the Patient
The physician should instruct patients to report any of the following side effects of androgens.
Adult or Adolescent Males: Too-frequent or persistent erections of the penis.
Women: Hoarseness, acne, changes in menstrual periods, or more hair on the face.
All Patients: Any nausea, vomiting, changes in skin color, or ankle swelling.
Any male adolescent patient receiving androgens for delayed puberty should have bone development checked every 6 months.
1. Women with disseminated breast carcinoma should have frequent determinations of urine and serum calcium levels during the course of androgen therapy (See WARNINGS).
2. Periodic (every 6 months) x-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.
3. Hemoglobin and hematocrit should be checked periodically for polycythemia in patients who are receiving high doses of androgens.
Drug/Laboratory Test Interferences
Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.Carcinogenesis Animal Data: testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma, testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.
Human Data: There are rare reports of hepatocellular carcinoma in patients receiving longterm therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.
Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma.
Usage in Pregnancy-Pregnancy Category X:
Teratogenic effects (See CONTRAINDICATIONS).
It is not known whether androgens are excreted in human milk, Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from androgens, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every 6 months by an x-ray of hand and wrist (See INDICATIONS AND USA - WARNINGS).
1.Oxyphenbutazone-Concurrent administration of oxyphenbutazone and androgens result in elevated serum levels of oxyphenbgutazone.
2. Insulin-In diabetic patients, the metabolic effects of androgens may decrease bl glucose and insulin requirements.
Endocrine and Urogenital
Female: The most common side effects of androgen therapy are amenorrhea and other menstrual irregularities, inhibition of gonadotropin secretion, and virilization, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after androgens are discontinued. When administered to a pregnant woman, androgens cause virilization of external genitalia of the female fetus.
Male: Gynecomastia, and excessive frequency and duration of penile erections. Oligospermia may occur at high dosages (See CLINICAL PHARMACOLOGY).
Skin and Appendages: Hirsutism, male pattern of baldness, and acne.
Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Patients with osteolytic neoplastic lesions who are bedfast or only semiambulatory may develop nephrocalcinosis when given either estrogens or androgens.
Gastrointestinal: Nausea and, rarely, hepatocellular neoplasms and peliosis hepatic (See WARNINGS).
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Metabolic: Increased serum cholesterol.
Miscellaneous: Inflammation and pain at the site of intramuscular injection, and , rarely, anaphylactoid reactions.
There have been no reports of acute overdosage with the androgens.
DOSAGE AND ADMINISTRATION:
1. Hypogonadism 250 mg intramuscular every 2-3 weeks. To maintain an adequate androgenic effect: 250 mg intramuscular every 3-4 weeks.
2. Infertility 50 mg intramuscular every 2 week for 90 days.
3. Potency disorders 100 mg intramuscular once a week. Continue treatment with 100 mg intramuscular, then 50 mg intramuscular every 2-4 weeks.
4. Male climacteric 50-100 mg intramuscular every 2-3 weeks. Repeated 6-8 weeks courses at 4 weeks intervals are recommended.
5. Body building: male: 300-2,000 mg per week, female: not recommended.
HOW SUPPLIED - TESTO 250® injection, solution- Intramuscular-250 mg is supplied in 1 ml ampoule 10 ampoule pack.
For shelf-life please refer to the imprint on Keep out of reach of children.
Should be at controlled room temperatures 15-30°C (59-86°F)
Do not freeze
This drug should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.
Protect from sun light
This drug has not been shown to be safe and effective for the enhancement of athletic performance!